Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma
AbstractNon-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), which targets the CD20 protein, present in over 80% of NHL mature B cells. Recent clinical reports show a preference for combining the benefits of immunotherapy and adjuvant chemotherapy, thus generating safe and effective alternative treatments. The current review aimed at evaluating various aspects related to the use of rituximab for NHL, highlighting the possible inhibitory mechanisms of cell proliferation, the achieved clinical results, and the expected clinical and economic outcomes of treatments. The results from clinical tests indicate the need for a better understanding of the critical mechanisms of action of this antibody, which may maximize its therapeutic efficacy. This therapy not only represents a viable option to treat most types of NHLs, especially when associated with conventional chemotherapy, but also offers cost-utility and cost-effectiveness advantages.
Download data is not yet available.
How to Cite
Figueirêdo, C. B. M., Souza, J. R. de, Soares, D. H. G., Silva, C. C. de A. R., & Lorena, V. M. B. de. (2014). Clinical and economic aspects of the use of rituximab in non-Hodgkin’s lymphoma . Brazilian Journal of Pharmaceutical Sciences, 50(3), 445-455. https://doi.org/10.1590/S1984-82502014000300002
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.